Related Experiment Videos
Immunofluorescence--still the 'gold standard' in ANA testing?
1Department of Clinical and Laboratory Medicine, Kobe University School of Medicine, Hyogo, Japan. kumagais@kobe-u.ac.jp
Summary
Enzyme immunoassay (EIA)-based antinuclear antibody (ANA) tests show superior performance for screening connective tissue disease (CTD) patients compared to immunofluorescence ANA assays (IF-ANA). EIA-ANA is recommended as a gold standard for large-scale screening.
Area of Science:
- Immunology
- Clinical Chemistry
- Autoimmunity
Background:
- Antinuclear antibodies (ANA) are key biomarkers for connective tissue diseases (CTD).
- Immunofluorescence ANA assay (IF-ANA) is a traditional method, but enzyme immunoassay (EIA)-based tests offer potential advantages.
Purpose of the Study:
- To evaluate the diagnostic utility of two EIA-based ANA tests (COBAS-ANA and MBL-ANA) against IF-ANA.
- To assess their efficacy in differentiating CTD patients from healthy individuals and detecting disease-specific ANAs.
Main Methods:
- Comparison of COBAS-ANA and MBL-ANA with IF-ANA using sera from 258 CTD patients and 257 healthy subjects.
- Evaluation of sensitivity, specificity, and receiver operating characteristic (ROC) analysis.
- Assessment of disease-specific ANA detection capabilities at various cutoff points.
Main Results:
- COBAS-ANA demonstrated higher sensitivity (84%) and specificity (94%) than IF-ANA (81% and 87% at 1:160 dilution).
- ROC analysis confirmed the superiority of COBAS-ANA over IF-ANA.
- Both EIA methods effectively detected disease-specific ANAs, with MBL-ANA showing potential for periodic health examinations.
Conclusions:
- EIA-based ANA tests are highly useful for screening CTD patients and detecting disease-specific ANAs.
- EIA-ANA should be considered the gold standard for large-scale ANA screening due to its superior performance.
- Further technical improvements may enhance the utility of EIA-ANA tests.